Phase 2 N=16 Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer
Advanced Colorectal Cancer
Primary: Best Response Rate — 1; 3; 4; 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=90 Topical Endoxifen in Women
Mammographic Breast Density
Primary: Change in Mammographic Breast Density At Study Exit — -1.85; -2.14; -3.75 percent change from baseline
Phase 2 N=44 Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma
Anaplastic Large Cell Lymphoma, ALK-Negative · Anaplastic Large Cell Lymphoma, ALK-Positive · Hepatosplenic T-Cell Lymphoma
Primary: Maximum Tolerated Dose (MTD) of Lenalidomide and CHOEP — 10 milligrams
Phase 2 N=93 Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer
Prostate Cancer Metastatic
Primary: Change in Frequency of Moderate to Severe Hot Flashes at 6 Weeks — -19.72; -42.24; -46.59 Percentage of change in frequency
Phase 2 N=101 Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)
Multiple Myeloma
Primary: Multiparametric Flow Cytometry - Minimum Residual Disease — 11; 13 Participants
Phase 2 N=54 Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients
Lymphoma
Primary: Number of Patients Achieving Complete Response (CR) — 4; 32 Participants
Phase 2 N=59 A Study Of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To Bone
Neoplasm Metastasis · Palliative Care
Primary: Change From Baseline in Daily Average Pain Intensity Numeric Rating Scale (NRS) Score at Week 6 — 5.4; 5.3; -1.3; -0.9 units on a scale — p=0.569
Phase 2 N=147 Cisplatin vs Paclitaxel for Triple Negative Breast Cancer
Triple Negative Breast Cancer
Primary: Number of Participants With Pathologic Response by HR-deficiency (HRD) Status — 9; 2; 10; 4 Participants
Phase 2 N=15 A Randomized Trial of CT Fluoroscopy-guided Targeted Autologous Blood and Fibrin Glue Patching for Treatment
Cerebrospinal Fluid Leaks
Primary: Change in Median (Headache Impact Test-6) HIT-6 Score From Baseline — -12; -7 score on a scale
Phase 2 N=7 Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer
NSCLC (Advanced Non-small Cell Lung Cancer)
Primary: Progression-Free Survival Following U3-1287 (AMG 888) in Combination With Erlotinib — 1.4; 2.5; 1.6 months
Phase 2 N=288 Efficacy and Safety of EGT0001442 in Patients With Type 2 Diabetes Mellitus
Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c at 24 Weeks — -0.28; 0.51 percentage of glycated hemoglobin — p=< 0.0001
Phase 2 N=193 Study to Find Out the Optimal Dose of Caffeine in the Combination Tablet of Naproxen Sodium and Caffeine in Patients Experiencing Moderate to Severe Pain After Having Wisdom Teeth Removed
Pain, Postoperative
Primary: Sum of Pain Intensity Difference (SPID) Over 8 Hours — 35.45; 37.87; 30.70; 36.02 Scores on a scale*hours
Phase 2 N=17 A Study of the Safety and Antiretroviral Activity of 3BNC117
HIV-1 Infection
Primary: Rate of Viral Rebound at 12 Weeks After Interruption of Antiretroviral Therapy — 13 Participants
Phase 2 N=220 RN624 In Adult Patients With Chronic Low Back Pain
Low Back Pain
Primary: Change From Baseline in Daily Average Low Back Pain Intensity (LBPI) Score at Week 6 — 6.48; 6.65; 6.67; -3.58 units on a scale — p=0.001
Phase 2 N=60 The Efficacy and Safety of Chlorhexidine Gluconate Chip (Periochip®) in Therapy of Symptoms in Patients With Peri-implantitis
Peri-implantitis
Primary: Change in Mean Probing Pocket Depth (PPD) for Selected Target Pocket — -2.13; -1.79 mm — p=0.1629